Dr Steven Bradshaw & Dr David Carr | 05/07/2015
Since the program's launch in April 2014, three 'promising innovative medicine' (PIM) designations have already been granted as part of the UK's Early Access to Medicines Scheme (EAMS). The venture, from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), is aimed to speed up access to as yet unlicensed medicines where there is a high unmet medical need.
PIM designation is the first in a two-step process, which recognizes a product as a good candidate fo...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
GenAI Life Science & Health 2025
September 1 - 3, 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More
DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More